Skip to main content
. 2019 Jul 25;4(14):e128643. doi: 10.1172/jci.insight.128643

Figure 8. Calpain inhibition results in partial rescue of desmoplakin levels in homozygous DSP R451G engineered heart tissues.

Figure 8

(A) Engineered heart tissues were incubated with 25 μM of the calpain inhibitor MDL-28170(MDL) or a vehicle control (DMSO) for 72 hours and then probed for desmoplakin protein levels. Loading across gels was normalized by sarcomeric actin. (Gel images are representative of PGP1 MDL n = 10; PGP1 DMSO, n = 8; HO35 MDL, n = 8; HO35 DMSO, n = 8). (B) Quantification of immunoblot showing significant interaction between genotype and drug treatment (P < 0.05) as well as significant loss of DSP between genotype (*P < 0.05) and drug treatment for 2-way ANOVA with Tukey’s multiple comparisons test. While desmoplakin levels in WT/WT EHTs were significantly decreased in samples exposed to MDL, this decrease was not observed in R451G/R451G EHTs.